Authors
Kryukov E.V., Panevin T.S.
The Main Military Clinical Hospital named after academician N.N. Burdenko of the Ministry of defence of the Russian Federation, Moscow
Abstract
Rationale: Climacteric myocardiodystrophy (CM) is a disease that not only leads to the quality of life worsening in females, but also has socioeconomic implications as a disease promoting the decrease in female workability. Whether changes of antithrombogenic vessel wall activity (ATVWA) occur in the peri- and postmenopausal period in this patient category remains unclear.
Study objective: analysis of antithrombogenic vessel wall activity in the peri- and postmenopausal period of females with climacteric myocardiodystrophy.
Materials and methods: The total number of females with CM was 330. Antithrombogenic vessel wall activity was evaluated based on anti-aggregation, anticoagulant, and fibrinolytic activity of vessel walls that were determined according to the method of M.V. Baluda.
Results: Out of 330 patients suffering from climacteric myocardiodystrophy, decreased anti-aggregation, anticoagulant, and fibrinolytic activity of the vessel wall was found in 199 women. Antithrombogenic vessel wall activity was normal in 131 females. With that, the decrease was statistically significant (p<0,001) for all three ATVWA components.
Conclusion: CM is characterized by decreased functional vessel wall adequacy in 60% patients on average.
Keywords: antithrombogenic vessel wall activity; climacteric myocardiodystrophy; menopausal hormone therapy.
References
1. Balabolkin MI, Klebanova EM, Kreminskaya VM. Syndromes caused by disorders of the sexual glands. In: Differential diagnosis and treatment of endocrine diseases. Moscow: Medicine; 2002. p.688–751.
2. Francoa ОН, Mukaa Т, Colpania V. Vasomotor symptoms in women and cardiovascular risk markers: systemic review and meta-analysis. Maturitas. 2015;81(3):353–361. Doi: 10.1016/j.maturitas.2015.04.016.
3. Zakharova LA. Mutual regulation of the development of the neuroendocrine and immune systems. Ontogenesis. 2010; 41(6):414–424.
4. Korneva EA. Immunophysiology as a new scientific direction: background and history of development. In: Immunophysiology. St. Petersburg: Nauka; 1993. p. 11–36.
5. Fenton А, Раnау N. Global consensus statement on menopausal hormone therapy – an update. Climacteric. 2016;19(4):311–312. Doi: 10.1080/13697137.2016.1202475.
6. Archer DF, Schmelter T, Schaefers M, et al. A randomimized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014;21(3):227–235. Doi: 10.1097/GME.0b013e31829c1431.
7. Girolami A, Sambado L, Lombardi AM. The impact of blood coagulability on atherosclerosis and cardiovascular disease: a rebuttal. J Thromb Haemost. 2013;11(1):213–216. Doi: 10.1111/jth.12030.
8. Baluda VP, Baluda MV, Deyanov II, et al. Physiology of the hemostatic system. Moscow; 1995. 243 p.
9. Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015;22(4):391–401. Doi: 10.1097/GME.0000000000000343.
10. Freynhofer MK, Bruno V, Wojta J, et al. The role of platelets in athero-thrombotic events. Curr Pharm Des. 2012;18(33):5197–5214. Doi: 10.2174/138161212803251899.
11. Gremmel T, Kopp CW, Eichelberger B, et al. Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis. 2014;237(2):692–695. Doi: 10.1016/j.atherosclerosis.2014.10.095.
12. Panevin TS. Menopausal hormone therapy and anti-platelet activity of blood vessels in patients with climacteric miocardiodistrofia. Bulletin of postgraduate education. 2019;2:46–50.
